Clinical Trial Update: Neoadjuvant Listeria or Daratumumab in Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating Listeria-based immunotherapy versus Daratumumab in prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Daratumumab (daratumumab)
• Listeria-based immunotherapy

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Male Genital Organs, Prostate Cancer | Phase 2 | Status: WITHDRAWN